Cellectis Q2 2026: Cash Runway into Q4 2027, Lasme-cel Pivotal Data Readout Expected Q4 2026
CLLS is trading near its 52-week low of $2.35 (14% above the low) on elevated volume (2.2× avg).
Summary
Cellectis posted Q2 2026 earnings with $169M cash (runway into Q4 2027), narrowed net loss, and set Q4 2026 catalysts: lasme-cel pivotal interim analysis and full Phase 1 eti-cel data.
Key Events · Earnings and Guidance · CLLS
-
Cash Runway Extended to Q4 2027
Cash, equivalents, and fixed-term deposits totaled $169 million as of June 30, 2026, down from $211 million at year-end 2025. Management expects this to fund operations into Q4 2027.
-
Lasme-cel Pivotal Interim Analysis in Q4 2026
The first interim analysis for the pivotal Phase 2 BALLI-01 trial in r/r B-ALL is now expected in Q4 2026. Lasme-cel holds FDA RMAT designation.
-
Eti-cel Full Phase 1 Data in Q4 2026
Full Phase 1 dataset from the NATHALI-01 trial in r/r NHL is expected in Q4 2026. Translational data presented at EHA 2026 showed 88% ORR and 63% CR in the optimal dose cohort.
-
Non-Cash Financial Gain Masks Operating Loss
Net financial gain of $9.2M in H1 2026 (vs. $18.1M loss in H1 2025) was driven by an $8.7M non-cash fair-value gain on EIB warrants. Operating loss widened to $48.7M from $23.8M.
Analysis · CLLS · Life Sciences
Cellectis reported Q2 2026 results with $169 million in cash, extending its runway into Q4 2027 — a critical survival metric for a pre-revenue biotech. The quarter also brought concrete clinical catalysts: the first interim analysis for the pivotal Phase 2 lasme-cel trial is now expected in Q4 2026, and full Phase 1 eti-cel data is due the same quarter. These near-term readouts could materially de-risk the pipeline. The net loss narrowed slightly year-over-year, but the headline financial gain was entirely non-cash — an $8.7 million fair-value gain on EIB warrants driven by share price movements, not operational improvement. Revenue dropped sharply as AstraZeneca collaboration activities slowed, while R&D costs rose on advancing trials. Against the backdrop of recently approved dilutive capital-raise authorizations, the cash position and upcoming data readouts are the story.
At the time of this filing, CLLS was trading at $2.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $207.5M. The 52-week trading range was $2.35 to $5.48. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.